Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 28.1% in September

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 16,900 shares, a decline of 28.1% from the September 15th total of 23,500 shares. Based on an average trading volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average trading volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Xenetic Biosciences currently has an average rating of “Reduce”.

Xenetic Biosciences Stock Up 4.0%

Shares of NASDAQ:XBIO opened at $3.86 on Friday. The company has a market cap of $5.94 million, a P/E ratio of -1.93 and a beta of 2.42. Xenetic Biosciences has a 52 week low of $2.20 and a 52 week high of $13.93. The business has a fifty day simple moving average of $3.67 and a 200-day simple moving average of $3.29.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.19. Xenetic Biosciences had a negative return on equity of 54.56% and a negative net margin of 126.08%.The firm had revenue of $0.59 million during the quarter, compared to the consensus estimate of $0.48 million. Sell-side analysts expect that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC raised its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,259 shares of the company’s stock after acquiring an additional 4,593 shares during the period. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 at the end of the most recent reporting period. 15.12% of the stock is owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.